ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 441,63
0,28%
Dow Jones
43 914,12
-0,53%
DAX
20 475,18
0,23%
Brent Oil
73,925
0,98%
Bitcoin
100 461,72
0,40%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Alvontech (ALVO)

  7. Alvontech (ALVO) Actualités

ALVO

Alvontech (ALVO)

Alvontech
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ALVO
DateHeureSourceTitreSymboleSociété
13/11/202422h05GlobeNewswire Inc.Alvotech Reports Financial Results for the First Nine Months of 2024NASDAQ:ALVOAlvontech
07/11/202414h00GlobeNewswire Inc.Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024NASDAQ:ALVOAlvontech
04/11/202413h00GlobeNewswire Inc.European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)NASDAQ:ALVOAlvontech
30/10/202413h30GlobeNewswire Inc.Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ETNASDAQ:ALVOAlvontech
25/10/202414h00GlobeNewswire Inc.Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024NASDAQ:ALVOAlvontech
22/10/202413h00GlobeNewswire Inc.Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)NASDAQ:ALVOAlvontech
10/10/202411h00GlobeNewswire Inc.European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®NASDAQ:ALVOAlvontech
25/09/202411h00GlobeNewswire Inc.Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®NASDAQ:ALVOAlvontech
26/08/202415h14GlobeNewswire Inc.Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:ALVOAlvontech
16/08/202411h57IH Market NewsH&R Block Shares Surge 10% on Profit and Dividend Boost, Applied Materials Drops 3% Despite Strong Earnings, Latest in EarningsNASDAQ:ALVOAlvontech
15/08/202422h15GlobeNewswire Inc.Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024NASDAQ:ALVOAlvontech
15/08/202412h09IH Market NewsU.S. Futures Rise on Easing Inflation, Oil Prices RiseNASDAQ:ALVOAlvontech
15/08/202410h30GlobeNewswire Inc.European Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)NASDAQ:ALVOAlvontech
01/08/202422h02GlobeNewswire Inc.Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ETNASDAQ:ALVOAlvontech
22/07/202412h30GlobeNewswire Inc.STADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across EuropeNASDAQ:ALVOAlvontech
11/07/202410h45GlobeNewswire Inc.Alvotech Announces Closing of Private Debt FinancingNASDAQ:ALVOAlvontech
02/07/202415h00GlobeNewswire Inc.Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®NASDAQ:ALVOAlvontech
01/07/202423h35GlobeNewswire Inc.Alvotech Issues New Shares to Holders of Convertible BondsNASDAQ:ALVOAlvontech
01/07/202411h10GlobeNewswire Inc.Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024NASDAQ:ALVOAlvontech
26/06/202410h50GlobeNewswire Inc.Alvotech Receives Conversion Notices for Majority of Convertible BondsNASDAQ:ALVOAlvontech
18/06/202410h01GlobeNewswire Inc.Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in EuropeNASDAQ:ALVOAlvontech
11/06/202410h00GlobeNewswire Inc.Alvotech and STADA add to strategic alliance through denosumab partnershipNASDAQ:ALVOAlvontech
07/06/202410h00GlobeNewswire Inc.Alvotech Announces Strategic Refinancing AgreementNASDAQ:ALVOAlvontech
29/05/202414h05GlobeNewswire Inc.Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024NASDAQ:ALVOAlvontech
21/05/202423h15GlobeNewswire Inc.Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business UpdateNASDAQ:ALVOAlvontech
21/05/202416h05Business WireAlvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UKNASDAQ:ALVOAlvontech
21/05/202414h00GlobeNewswire Inc.Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKNASDAQ:ALVOAlvontech
21/05/202413h13IH Market NewsU.S. Index Futures Open Lower Amid Nasdaq Record, Fed SpeechesNASDAQ:ALVOAlvontech
21/05/202402h25Business WireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.NASDAQ:ALVOAlvontech
13/05/202414h00GlobeNewswire Inc.Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)NASDAQ:ALVOAlvontech
 Showing the most relevant articles for your search:NASDAQ:ALVO

Dernières Valeurs Consultées

COIN
XRPUSD
Ripple
EU
DG
Vinci
EU
CS
Axa
EU
MC
Lvmh Moet Hennessy Louis...
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
EU
PX4
SBF 120
NASDAQ
GOOGL
Alphabet
EU
AI
Air Liquide
NYSE
MCD
McDonalds
EU
VK
Vallourec
SPI
SP500
S&P 500
EU
RNO
Renault
NASDAQ
AMZN
Amazon.com
COIN
ETHUSD
Ethereum
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés